Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price target remains the same with $45.00. Mitchell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback